LQDA Liquidia Technologies Inc

Liquidia Corporation (NASDAQ:LQDA) has received a consensus rating of "Moderate Buy" from ten research firms, with an average 1-year price target of $38.56. The company recently exceeded earnings expectations, reporting an EPS of ($0.04) against an estimated ($0.45), and revenue of $54.34 million, significantly higher than the $18.86 million expected. Despite positive analyst sentiment and strong revenue growth, Liquidia remains unprofitable and has seen insider selling activity totaling approximately $4.5 million over the past 90 days.

BTIG Research has reiterated a "Buy" rating for Liquidia (NASDAQ:LQDA), setting a price target of $49.00, which suggests a 38.11% upside. Other analysts have a mixed view, with an average "Moderate Buy" rating and a target of $38.56. Despite a recent revenue beat and smaller-than-expected quarterly loss, the company remains unprofitable with insider selling activity observed.

BTIG analyst Julian Harrison has reiterated a 'Buy' rating for Liquidia (LQDA) with a consistent price target of $49.00. This follows several prior analyst actions, including other 'Buy' ratings and price target increases from firms like Needham and HC Wainwright & Co. Liquidia is a biopharmaceutical company focused on treating pulmonary hypertension using its proprietary PRINT technology.

Analysts have reaffirmed a bullish stance on Liquidia (LQDA) following positive quarterly results, driving a significant increase in share price, up 19.82% over the past month and 195.79% year-to-date. Despite concerns about its high 45x price-to-sales ratio compared to a fair value of 16.3x and the sector average of 4.4x, a Discounted Cash Flow (DCF) model suggests the company might be deeply undervalued, indicating a fair value of $196.66 against its current trading price of $35.79. The ongoing YUTREPIA patent dispute remains a key driver of investor attention and a potential risk.

New options for Liquidia Corp (LQDA) for the February 2026 expiration began trading today. Investors can consider a put contract at a $35.50 strike price offering a potential 8.45% return if it expires worthless, or a covered call at a $36.50 strike price providing a 10.37% total return if the stock is called away. These options present attractive annualized returns and strategies for investors wishing to purchase or hold LQDA shares.

Liquidia Corp. was unsuccessful in its attempt to dismiss a patent infringement lawsuit filed by United Therapeutics Corp. concerning its lung-disease drug Yutrepia. A federal judge ruled that the current lawsuit's claims are distinct from previous litigation, involving a different patent, thus preventing dismissal based on serial litigation arguments. This decision means the case will proceed in the U.S. District Court for the Middle District of North Carolina.